HAEMOPHILIA A
Clinical trials for HAEMOPHILIA A explained in plain language.
Never miss a new study
Get alerted when new HAEMOPHILIA A trials appear
Sign up with your email to follow new studies for HAEMOPHILIA A, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New clotting drug cuts bleeding in severe hemophilia a study
Disease control CompletedThis study tested a medicine called turoctocog alfa pegol (N8-GP) in 36 Chinese men with severe hemophilia A, a condition where blood does not clot properly. Participants received regular injections to prevent bleeding episodes and additional doses when bleeding occurred. The mai…
Matched conditions: HAEMOPHILIA A
Phase: PHASE3 • Sponsor: Novo Nordisk A/S • Aim: Disease control
Last updated May 26, 2026 12:12 UTC
-
New pen injector could make hemophilia treatment easier
Disease control CompletedThis study tested a new pen injector for giving the medicine Mim8, which helps control bleeding in people with hemophilia A. The goal was to see if the pen injector delivers the same amount of medicine into the blood as a standard syringe. The study involved 205 healthy men and l…
Matched conditions: HAEMOPHILIA A
Phase: PHASE1 • Sponsor: Novo Nordisk A/S • Aim: Disease control
Last updated May 26, 2026 12:05 UTC
-
New shot Mim8 shows promise in preventing bleeds for hemophilia a patients
Disease control CompletedThis study looked at how safe it is for people with hemophilia A to switch from their current medicine (emicizumab) to a new one called Mim8. Mim8 is injected under the skin weekly, every two weeks, or monthly to help prevent bleeding episodes. The study involved 61 adults and te…
Matched conditions: HAEMOPHILIA A
Phase: PHASE3 • Sponsor: Novo Nordisk A/S • Aim: Disease control
Last updated May 26, 2026 12:02 UTC
-
New shot could slash bleeding episodes for hemophilia patients
Disease control CompletedThis study tested a new medicine called Mim8 in 281 adults and teens with hemophilia A, including those with inhibitors. Mim8 helps replace missing clotting factor to prevent bleeding episodes. Participants received injections once a week or once a month. The study lasted up to 2…
Matched conditions: HAEMOPHILIA A
Phase: PHASE3 • Sponsor: Novo Nordisk A/S • Aim: Disease control
Last updated May 22, 2026 14:02 UTC
-
New hope for young kids with severe bleeding disorder: safer clotting factor studied
Disease control CompletedThis study tested a new medicine called N8-GP (turoctocog alfa pegol) in 124 young children under 6 with severe haemophilia A who had never been treated before. The goal was to see if it safely prevents and treats bleeding episodes. The medicine is a longer-acting clotting factor…
Matched conditions: HAEMOPHILIA A
Phase: PHASE3 • Sponsor: Novo Nordisk A/S • Aim: Disease control
Last updated May 19, 2026 11:59 UTC
-
Healthy men test new hemophilia drug Inno8 for safety
Knowledge-focused CompletedThis study tested a new medicine called Inno8 in 95 healthy men to see if it is safe. The medicine is being developed for people with hemophilia A, a bleeding disorder. Participants received either Inno8 or a placebo by injection or as a tablet. The results will help decide if In…
Matched conditions: HAEMOPHILIA A
Phase: PHASE1 • Sponsor: Novo Nordisk A/S • Aim: Knowledge-focused
Last updated May 20, 2026 11:57 UTC